Standout Papers

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olapar... 2016 2026 2019 2022 303
  1. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial (2016)
    Jonathan A. Ledermann, Philipp Harter et al. The Lancet Oncology

Immediate Impact

13 from Science/Nature 65 standout
Sub-graph 1 of 22

Citing Papers

Oxygen‐carrying semiconducting polymer nanoprodrugs induce sono‐pyroptosis for deep‐tissue tumor treatment
2024 Standout
PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends
2024 Standout
3 intermediate papers

Works of Philip Rowe being referenced

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
2016 Standout
Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.
2016

Author Peers

Author Last Decade Papers Cites
Philip Rowe 322 195 149 7 380
Dale W. Garsed 240 118 184 9 369
Alison Freimund 265 120 138 11 360
Dana‐Adriana Botesteanu 297 117 159 9 398
Aparajitha Vaidyanathan 270 60 242 7 390
Ashleigh Herriott 351 36 250 6 396
Heather Derocher 278 49 60 6 391
Tabari M. Baker 257 38 227 12 393
Jeffrey Evans 331 24 271 6 412
Colleen Crane 114 129 210 5 393
Gonzalo Giornelli 96 220 78 7 377

All Works

Loading papers...

Rankless by CCL
2026